Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that it plans to report its financial results for its fiscal fourth
quarter and year ended September 30, 2015 after the U.S. markets close
on November 23, 2015. Enanta management will host a conference call at
4:30 p.m. ET to discuss these results and provide an update on Enanta’s
research and development pipeline.
Conference Call and Webcast Information
To participate in
the live conference call, please dial (855) 840-0595 in the U.S. or
(518) 444-4814 for international callers. A replay of the conference
call will be available starting at approximately 7:30 p.m. Eastern time
on November 23, 2015, through 11:59 p.m. Eastern time on November 30,
2015 by dialing (855) 859-2056 from the U.S. or (404) 537-3406 for
international callers. The passcode for both the live call and the
replay is 58326369. A live audio webcast of the call and replay can be
accessed by visiting the “Calendar of Events” section on the “Investors”
page of Enanta’s website at www.enanta.com.
About Enanta
Enanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases. Enanta has
developed novel protease and NS5A inhibitors that are members of the
direct-acting-antiviral (DAA) inhibitor classes designed for use against
the hepatitis C virus (HCV). Enanta’s protease inhibitors partnered with
AbbVie include paritaprevir, which is contained in AbbVie’s marketed DAA
regimens for HCV, and ABT-493, Enanta’s next-generation protease
inhibitor completing phase 2 development in combination with ABT-530,
AbbVie’s next-generation NS5A inhibitor. Enanta also has a program to
develop a host-targeted antiviral (HTA) inhibitor class for HCV targeted
against cyclophilin, as well as another DAA program to develop
nucleotide polymerase inhibitors. In addition, Enanta has a preclinical
program in non-alcoholic steatohepatitis, or NASH, which is a condition
that results in liver inflammation and liver damage caused by a buildup
of fat in the liver.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151113005034/en/
Copyright Business Wire 2015